Table 1 Baseline demographic, anthropometric, clinical and routine laboratory characteristics of the study participants
From: Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis
Baseline Characteristics | Total Population, n = 79 | Klotho≤745, n = 40 | Klotho> 745, n = 39 | P |
|---|---|---|---|---|
Male, n(%) | 50 (63.3) | 26 (65.5%) | 24 (61.5%) | 0.750 |
Age (years) | 59.7 ± 15.8 | 61.5 ± 16.1 | 58.1 ± 15.0 | 0.158 |
ΒΜΙ (kg/m2) | 24.7 ± 4.1 | 25.3 ± 4.6 | 24.3 ± 3.6 | 0.307 |
Dialysis vintage (months) | 65.5 ± 54.3 | 63.7 ± 52.5 | 70.5 ± 57.3 | 0.583 |
Hypertension, n (%) | 57 (72.2%) | 33 (82.5%) | 24 (61.5%) | 0.038 |
Diabetes, n (%) | 17 (21.5%) | 11 (27.5%) | 6 (15.4%) | 0.190 |
CVD history, n (%) | 29 (36.7%) | 18 (45.0%) | 11 (28.2%) | 0.122 |
Smokers, n(%) | 25 (31.6%) | 11 (27.5%) | 14 (35.9%) | 0.422 |
SBP (mmHg) | 136.7 ± 18.4 | 136.2 ± 18.4 | 138.4 ± 17.6 | 0.621 |
DBP (mmHg) | 84.1 ± 11.6 | 84.9 ± 12.8 | 84.1 ± 10.5 | 0.619 |
Pulse pressure (mmHg) | 53.0 ± 13.9 | 49.7 ± 12.7 | 54.2 ± 16.2 | 0.322 |
cfPWV (m/s) | 9.9 ± 2.3 | 10.1 ± 2.5 | 9.8 ± 2.1 | 0.565 |
ccIMT (mm) | 0.83 ± 0.16 | 0.86 ± 0.16 | 0.79 ± 0.15 | 0.034 |
Klotho (pg/mL) | 796.1 ± 236.8 | 661.3 ± 74.5 | 934.4 ± 265.7 | < 0.001 |
iFGF23(pg/mL) | 794.4 ± 1393.7 | 879.7 ± 1449.7 | 726.2 ± 1401.8 | 0.151 |
cFGF23(RU/mL) | 6730.8 ± 10,113.0 | 6777.1 ± 11,211.3 | 6733.0 ± 9367.1 | 0.638 |
kt/v | 1.46 ± 0.21 | 1,48 ± 0.20 | 1.44 ± 0.22 | 0.409 |
HDF | 34 (43%) | 15 (37.5%) | 19 (48.7%) | 0.314 |
Hemoglobin (g/dl) | 11.3 ± 1.1 | 11.4 ± 1.3 | 11.3 ± 1.1 | 0.814 |
Creatinine (mg/dl) | 9.24 ± 2.11 | 9.14 ± 1.89 | 9.34 ± 2.32 | 0.715 |
Urea (mg/dl) | 132.7 ± 33.2 | 122.8 ± 29.9 | 138.3 ± 33.6 | 0.199 |
Albumin (g/dl) | 4.02 ± 0.33 | 4.03 ± 0.34 | 3.97 ± 0.38 | 0.426 |
Cholesterol (mg/dl) | 150.8 ± 38.8 | 151.7 ± 49.1 | 152.5 ± 29.3 | 0.433 |
Triglycerides (mg/dl) | 140.2 ± 64.4 | 150.5 ± 68.6 | 128.9 ± 39.3 | 0.201 |
LDL-Cholesterol (mg/dl) | 74.1 ± 32.1 | 78.5 ± 42.1 | 72.9 ± 23.3 | 0.442 |
HDL-Cholesterol (mg/dl) | 45.1 ± 14.1 | 43.6 ± 13.9 | 48.4 ± 14.7 | 0.078 |
Serum calcium (mg/dl) | 8.84 ± 0.70 | 8.83 ± 0.77 | 8.78 ± 0.60 | 0.316 |
Serum phosphate (mg/dl) | 5.23 ± 1.45 | 5.08 ± 1.42 | 5.36 ± 1.56 | 0.834 |
Ca x P (mg2/dl2) | 46.3 ± 13.3 | 46.9 ± 13.8 | 46.3 ± 13.1 | 0.869 |
iPTH (pmol/L) | 38.5 ± 29.4 | 38.9 ± 31.9 | 39.2 ± 28.0 | 0.673 |
Alkaline phosphatase (U/L) | 94.4 ± 40.2 | 95.9 ± 44.9 | 101.4 ± 40.5 | 0.267 |
CRP (mg/L) | 7.34 ± 9.39 | 9.51 ± 13.56 | 5.94 ± 5.96 | 0.342 |
Intake of antihypertensive agents | 57 (72.2%) | 33 (82.5%) | 24 (61.5%) | 0.038 |
ESA | 61 (77.2%) | 30 (75%) | 31 (79.5%) | 0.479 |
Vit D and analogues | 45 (57%) | 22 (55%) | 23 (59%) | 0.721 |
Intravenous Iron | 71 (89.9%) | 35 (87.5%) | 36 (92.3%) | 0.479 |
Statins | 29 (36.7%) | 17 (42.5%) | 12 (30.8%) | 0.279 |